Terms: = Kidney tumors AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1
750 results:
1. Histomorphometric and Immunohistochemical Diagnosis of Renal Cell Carcinoma: Review Article.
Deka D; Chakravarty M
Mymensingh Med J; 2024 Apr; 33(2):636-642. PubMed ID: 38557550
[TBL] [Abstract] [Full Text] [Related]
2. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract] [Full Text] [Related]
3. Plasma metabolites and risk of seven cancers: a two-sample Mendelian randomization study among European descendants.
Chen Y; Xie Y; Ci H; Cheng Z; Kuang Y; Li S; Wang G; Qi Y; Tang J; Liu D; Li W; Yang Y
BMC Med; 2024 Mar; 22(1):90. PubMed ID: 38433226
[TBL] [Abstract] [Full Text] [Related]
4. Analysis of surgical site infection and tumour-specific survival rate in patients with renal cell carcinoma after laparoscopic radical nephrectomy.
Meng S; Meng M; Wang S; Zheng W
Int Wound J; 2024 Feb; 21(2):e14711. PubMed ID: 38387886
[TBL] [Abstract] [Full Text] [Related]
5. Exosomal long non-coding RNA MALAT1: a candidate of liquid biopsy in monitoring of Wilms' tumor.
Sharma D; Singh A; Wilson C; Swaroop P; Kumar S; Yadav DK; Jain V; Agarwala S; Husain M; Sharawat SK
Pediatr Surg Int; 2024 Feb; 40(1):57. PubMed ID: 38353772
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive review of amino acid transporters as therapeutic targets.
Xia R; Peng HF; Zhang X; Zhang HS
Int J Biol Macromol; 2024 Mar; 260(Pt 2):129646. PubMed ID: 38272411
[TBL] [Abstract] [Full Text] [Related]
7. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
8. Long-term outcomes after surgical resection of pancreatic metastases from renal Clear-cell carcinoma.
Boubaddi M; Marichez A; Adam JP; Chiche L; Laurent C
Eur J Surg Oncol; 2024 Feb; 50(2):107960. PubMed ID: 38219701
[TBL] [Abstract] [Full Text] [Related]
9. A Bayesian functional approach to test models of life course epidemiology over continuous time.
Bodelet J; Potente C; Blanc G; Chumbley J; Imeri H; Hofer S; Harris KM; Muniz-Terrera G; Shanahan M
Int J Epidemiol; 2024 Feb; 53(1):. PubMed ID: 38205821
[TBL] [Abstract] [Full Text] [Related]
10. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC; Garralda E; Schöffski P; Hong DS; Siu LL; Martin M; Maur M; Hui R; Soo RA; Chiu J; Zhang T; Ma B; Kyi C; Tan DS; Cassier PA; Sarantopoulos J; Weickhardt A; Carvajal RD; Spratlin J; Esaki T; Rolland F; Akerley W; Deschler-Baier B; Rispoli L; Samant TS; Chowdhury NR; Gusenleitner D; Kwak EL; Askoxylakis V; De Braud F
Oncoimmunology; 2024; 13(1):2290787. PubMed ID: 38170160
[TBL] [Abstract] [Full Text] [Related]
11. Association between circadian physical activity patterns and cancer incidence through regulation of inflammation: A UK biobank study.
Bai P; Ning X; Gao R; Shao X; Zhou S; Li J; Lin Y; Liu H; Zhang M; Yu P
Prev Med; 2024 Feb; 179():107831. PubMed ID: 38145876
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract] [Full Text] [Related]
13. Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step.
Le Blanc J; Projean D; Savignac S; Léveillé S; Ducas MP; Brisebois-Boyer A; Marsot A
Clin Pharmacokinet; 2024 Feb; 63(2):183-196. PubMed ID: 38127240
[TBL] [Abstract] [Full Text] [Related]
14. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
[TBL] [Abstract] [Full Text] [Related]
15. Off-clamp vs on-clamp robot-assisted partial nephrectomy: a systematic review and meta-analysis.
Fong KY; Gan VHL; Lim BJH; Chan YH; Castellani D; Chen K; Tay KJ; Ho HSS; Yuen JSP; Aslim E; Teoh J; Lim EJ
BJU Int; 2024 Apr; 133(4):375-386. PubMed ID: 38069544
[TBL] [Abstract] [Full Text] [Related]
16. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
[TBL] [Abstract] [Full Text] [Related]
17. Computational analysis of protein-protein interactions of cancer drivers in renal cell carcinoma.
Pei J; Zhang J; Cong Q
FEBS Open Bio; 2024 Jan; 14(1):112-126. PubMed ID: 37964489
[TBL] [Abstract] [Full Text] [Related]
18. Utilization of muscle area in an accurate prediction formula for renal function for patients with hepatocellular carcinoma.
Hayashi H; Shimizu A; Kubota K; Kitagawa N; Notake T; Masuo H; Yoshizawa T; Sakai H; Yasukawa K; Soejima Y
Asian J Surg; 2024 Feb; 47(2):893-898. PubMed ID: 37923599
[TBL] [Abstract] [Full Text] [Related]
19. Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma.
Sun Z; Wang J; Fan Z; Yang Y; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Liu Y; Yang Q; Ma B
J Gene Med; 2024 Jan; 26(1):e3608. PubMed ID: 37897262
[TBL] [Abstract] [Full Text] [Related]
20. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
[TBL] [Abstract] [Full Text] [Related]
[Next]
